134531-63-8 Usage
Uses
Used in Pharmaceutical Industry:
6-oxo-1,6-dihydropyridine-3-carboxylic acid hydrazide is used as a pharmaceutical agent for its potential therapeutic effects in treating various diseases. Its anti-inflammatory properties make it a candidate for the treatment of inflammatory conditions, while its antitumor activity suggests its potential use in cancer therapy.
Used in Anticancer Applications:
In the field of oncology, 6-oxo-1,6-dihydropyridine-3-carboxylic acid hydrazide is used as an anticancer agent. Its ability to target and inhibit the growth of cancer cells makes it a promising compound for further research and development in cancer treatment.
Used in Antimicrobial Applications:
6-oxo-1,6-dihydropyridine-3-carboxylic acid hydrazide is also used as an antimicrobial agent due to its broad-spectrum activity against various microorganisms. This property makes it a potential candidate for the development of new antibiotics and antifungal agents to combat drug-resistant infections.
Used in Drug Discovery:
The unique chemical structure and properties of 6-oxo-1,6-dihydropyridine-3-carboxylic acid hydrazide make it a valuable compound in drug discovery. Researchers can use 6-oxo-1,6-dihydropyridine-3-carboxylic acid hydrazide as a starting point for the design and synthesis of new drugs with improved pharmacological properties and therapeutic potential.
Check Digit Verification of cas no
The CAS Registry Mumber 134531-63-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,4,5,3 and 1 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 134531-63:
(8*1)+(7*3)+(6*4)+(5*5)+(4*3)+(3*1)+(2*6)+(1*3)=108
108 % 10 = 8
So 134531-63-8 is a valid CAS Registry Number.
InChI:InChI=1/C6H7N3O2/c7-9-6(11)4-1-2-5(10)8-3-4/h1-3H,7H2,(H,8,10)(H,9,11)
134531-63-8Relevant academic research and scientific papers
Ling,Hong,Gonzalez,Gregor,Polinsky,Kuki,Shi,Teston,Murphy,Porter,Kiel,Lakis,Anderes,May,Knudsen,Lau
, p. 3141 - 3149 (2001)
High throughput screening of our small molecule combinatorial library identified a class of benzoylnaphthalenehydrazones with modest affinity for the human glucagon receptor. Optimization of this initial hit through a series of targeted libraries and traditional medicinal chemistry led to ligands with nanomolar affinities. Pharmacological evaluation demonstrated that these ligands were competitive glucagon receptor antagonists. Intravenous administration of a representative benzoylnaphthalenehydrazone into rats attenuated glucagon-stimulated glucose levels.
